Market Cap | 301.76M | P/E | 18.02 | EPS this Y | -54.50% | Ern Qtrly Grth | -63.70% |
Income | 6.04M | Forward P/E | 15.07 | EPS next Y | 150.00% | 50D Avg Chg | -11.00% |
Sales | 193.61M | PEG | - | EPS past 5Y | 9.78% | 200D Avg Chg | -29.00% |
Dividend | N/A | Price/Book | 4.79 | EPS next 5Y | - | 52W High Chg | -52.00% |
Recommedations | 1.70 | Quick Ratio | 2.99 | Shares Outstanding | 31.74M | 52W Low Chg | 1.00% |
Insider Own | 51.49% | ROA | 4.80% | Shares Float | 15.44M | Beta | 0.54 |
Inst Own | 30.51% | ROE | 12.70% | Shares Shorted/Prior | 5.44M/5.50M | Price | 8.29 |
Gross Margin | 80.00% | Profit Margin | 3.12% | Avg. Volume | 363,783 | Target Price | 17.25 |
Oper. Margin | 4.46% | Earnings Date | Oct 24 | Volume | 523,244 | Change | -3.83% |
Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
HC Wainwright & Co. | Buy | Sep 4, 24 |
RBC Capital | Outperform | Jul 26, 24 |
HC Wainwright & Co. | Buy | Jul 26, 24 |
RBC Capital | Outperform | Jun 14, 24 |
HC Wainwright & Co. | Buy | May 1, 24 |
RBC Capital | Outperform | Mar 1, 24 |
HC Wainwright & Co. | Buy | Mar 1, 24 |
RBC Capital | Outperform | Oct 16, 23 |
HC Wainwright & Co. | Buy | Apr 28, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Sandgaard Thomas | PRESIDENT, CEO AND C.. PRESIDENT, CEO AND CHAIRMAN | Oct 16 | Option | 0.20 | 209,000 | 41,800 | 14,604,465 | 10/17/23 |
MOORHEAD DANIEL J | Chief Financial Offi.. Chief Financial Officer | Aug 04 | Sell | 8.49 | 20,000 | 169,800 | 24,179 | 08/07/23 |
Lucsok Anna | Chief Operating Offi.. Chief Operating Officer | Aug 04 | Sell | 8.41 | 12,000 | 100,920 | 17,840 | 08/07/23 |
Lucsok Anna | Chief Operating Offi.. Chief Operating Officer | Dec 13 | Sell | 13.98 | 1,103 | 15,420 | 13,973 | 12/13/22 |
MOORHEAD DANIEL J | Chief Financial Offi.. Chief Financial Officer | Oct 29 | Sell | 10.68 | 38,126 | 407,186 | 18,405 | 11/01/22 |
MOORHEAD DANIEL J | Chief Financial Offi.. Chief Financial Officer | Jun 14 | Sell | 16.2 | 25,000 | 405,000 | 13,483 | 06/14/21 |